CSIMarket
 
Adial Pharmaceuticals Inc   (ADIL)
Other Ticker:  
 
 
Price: $1.6300 $0.05 3.165%
Day's High: $1.75 Week Perf: -14.21 %
Day's Low: $ 1.54 30 Day Perf: 40.52 %
Volume (M): 316 52 Wk High: $ 6.50
Volume (M$): $ 516 52 Wk Avg: $1.52
Open: $1.54 52 Wk Low: $0.20



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0

Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in Charlottesville, Virginia. The company focuses on the development of precision medicines for the treatment of alcohol use disorder (AUD) and other addictive disorders. Adial Pharmaceuticals' lead product is AD04, a therapeutic compound designed to reduce the desire to consume alcohol. The company aims to address the significant unmet need for effective pharmacotherapies for AUD, which currently lacks adequate treatment options. Adial Pharmaceuticals is committed to improving the lives of individuals suffering from alcohol addiction through innovative research and development efforts.


   Company Address: 1180 Seminole Trail Charlottesville 22901 VA
   Company Phone Number: 422-9800   Stock Exchange / Ticker: NASDAQ ADIL
   ADIL is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Adial Pharmaceuticals Unveils Promising Partnership: $83 Million Potential to Transform Addiction Treatment

Published Wed, Dec 20 2023 2:00 PM UTC

Adial Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on addiction therapeutics, has recently announced the receipt of the final development cost reimbursement payment of $350,000 from Adovate, LLC. This payment marks a significant milestone in their business agreement and sets the stage for potential groundbreaking discoveries in addiction and related d...

Stock Market Announcement

Adial Pharmaceuticals: Pioneering Addiction Treatment Solutions and Reclaiming Regulatory Compliance

Published Wed, Nov 29 2023 9:05 PM UTC

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Rule, Strengthens Position in Addiction Treatment Market
Charlottesville, Va. - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company specializing in the development of therapies for addiction and related disorders, announced today that it has received notice from Nasdaq ...

Adial Pharmaceuticals Inc

ADIL Surprises Shareholders with Impressive Financial Turnaround in Q3 2023

The stock market has been buzzing with excitement as companies in various industries release their earnings reports for the third quarter of 2023. One industry that has garnered attention is Major Pharmaceutical Preparations, with several companies reporting their financial results. Among them, ADIL, a prominent player in the industry, has recently published its operating deficit for the quarter, and the numbers look promising.
ADIL announced an operating deficit of $-1.357936 million, indicating a significant improvement from the same reporting season last year, where the deficit stood at $-3.187693 million. This revelation is undoubtedly a positive sign for the company and has caught the attention of market observers. It demonstrates that ADIL's management has implemented efficient strategies to streamline operations and reduce losses.

Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc: Overcoming Challenges and Paving the Way for Innovation



Adial Pharmaceuticals Inc, a major player in the Major Pharmaceutical Preparations industry, recently released its financial results for the second quarter of 2023. While the company faced an operating shortfall, there are noteworthy aspects that indicate positive developments. This article aims to interpret these financial results and analyze their potential impact on the company's future prospects.
Operating Shortfall in Q2 2023:
Adial Pharmaceuticals Inc announced an operating shortfall of $-1.477395 million for the second quarter of 2023. However, the company's performance in day-to-day operations during this period has shown improvement compared to the same quarter the previous year. This suggests that the management has successfully addressed underlying issues and is making progress in enhancing operations.
Diversification into the Research Cycle:
One major take-away from these financial results is that Adial Pharmaceuticals Inc primarily operates in the research cycle. While this segment might be less prominent compared to other areas within the industry, it indicates the company's focus on innovation and development. By investing in research and development, Adial Pharmaceuticals Inc is positioning itself for future growth and potential breakthroughs.

Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc Reports Disappointing $13 Million Operating Loss in Q1 2023, Leading to Negative ROI

Adial Pharmaceuticals Inc Records $-13 Million Loss in Q1 2023 Resulting in Negative ROI, But Progress Made on Overall Ranking
In its recent financial report, Adial Pharmaceuticals Inc reported a cumulative net loss of $-13 million in the first quarter of 2023. This has resulted in negative return on investment (ROI) of -236.64%. While this news was disappointing for investors, it is important to note that the healthcare sector had 623 other companies with higher ROI.
However, on a positive note, the overall ROI ranking has progressed to 3184 in the Mar 31, 2023 quarter from the total ROI ranking of 4613 in the fourth quarter of 2022. The Major Pharmaceutical Preparations sector consultants have started to interpret the first quarter of 2023 earnings.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com